- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05453227
Zinc Containing Vaginal Topical " Suppository "
Zinc Containing Vaginal Topical " Suppository " in Improving Post Menopausal Genitourinary Syndrome: "Double Blind Controlled Study "
The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs associated with physical changes of the vulva, vagina, and lower urinary tract.
The GSM includes not only genital symptoms (dryness, burning, and irritation) and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function), but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections [UTI])
Study Overview
Detailed Description
The terms vulvovaginal atrophy and atrophic vaginitis were widely used until recently, but they have been considered to be inadequate for referring to the constellation of symptoms and signs associated with the genitourinary system after menopause.
The term vulvovaginal atrophy mentions the vulva and vagina only, and these words are not used comfortably in general social discussion and in the media. The term atrophic vaginitis implies a state of inflammation or infection, which is not a primary component of menopausal changes. In addition, a limitation of the terms vulvovaginal atrophy and atrophic vaginitis is that they do not take into account the symptoms of the lower urinary tract, which are among the most important symptoms related to menopause.
Vulvovaginal atrophy (VVA) is a prevalent condition affecting many postmenopausal women.1 Up to 40% of postmenopausal women develop symptoms of VVA.
It is most often diagnosed by its symptoms, including vaginal dryness, burning, itching, vagina pain and dyspareunia. More recently these symptoms have been described as a syndrome: the genitourinary syndrome of menopause (GSM).
This new term describes various menopausal symptoms and signs including not only genital symptoms but sexual (pain) and urinary symptoms (dysuria, urgency) as well.
The pathophysiology of GSM/VVA can be explained by the decline in estrogen levels associated with diminished ovarian function and natural aging.
Traditionally the treatment options for GSM/VVA was vaginal estrogen supplementation but many women are either unable to or are afraid to use hormones. There are several non-hormonal treatment modalities for the management of VVA related symptoms, especially for one of the most bothersome symptoms of vaginal dryness.
The 2013 position statement of The North American Menopause Society indicates that the first-line therapies to alleviate symptoms of VVA should include non-hormonal vaginal lubricants and moisturizers as well as regular sexual activity.
Although there are numerous vaginal moisturizers and lubricants are commercially available only a few of those have been tested in clinical trials.
Previously the investigators showed the role of vaginal zinc supplementation on vaginal remodeling. The investigators showed that in human vaginal smooth muscle cells, zinc has a beneficial effect on the production of extracellular components produced by the muscle at 20 μM zinc tissue level, thereby increasing the amount of elastin production.
Earlier animal studies have shown that zinc plays an important role in the vaginal extracellular matrix (ECM) composition. When rats were kept on a zinc-lacking diet, the vaginal structure became similar to the menopausal vagina.With vaginal zinc replacement, the vaginal ECM could be regenerated with characteristics equivalent to juvenile rats .
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Elmenofia
-
Cairo, Elmenofia, Egypt
- Al-Azhar University Hospitals and Ashmoun central hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- presence of symptoms of vulvovaginal atrophy/GSM in postmenopausal women. including vaginal dryness, burning, itching, vagina pain and dyspareunia. To be defined as a postmenopausal woman.
individuals had to have at least 12 consecutive months of amenorrhea without any other obvious reason/or consistently elevated follicle-stimulating hormone blood levels of 30 mIU/mL or higher.
Exclusion Criteria:
- premenopausal state,
- local or systemic hormone therapy within the past six months
- vaginal infection at presentation
- cytological atypia
- prior radiation treatment
- history of breast, ovarian or other gynecological cancer
- pelvic organ prolapse > stage 2
- recent use (3 months) of any vaginal product or douching.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Zinc Group
25 cases will be undergo treatment with active ingredient
|
To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
|
Placebo Comparator: Plcebo Group
25 cases will be undergo treatment with placebo
|
To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The using of novel zinc-containing vaginal suppositories
Time Frame: From baseline to 2 weeks after using the zinc sulphate
|
Assessment of postmenopausal symptoms as dryness, burning, and irritation by Vaginal Health Index (VHI) score: elasticity, fluid secretion, pH and epithelial mucosa (integrity) and moisture components.
Each component is scored on a scale of 1 (worst) to 5 (best).
Lower scores indicate more severe atrophy.
VHI was calculated at baseline and 2 weeks after the treatment.
|
From baseline to 2 weeks after using the zinc sulphate
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Assem Anwar, Professor, Department of Obstetrics & Gynecology Faculty of Medicine for boys, Al-Azhar University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Bahaa Mohamed
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genitourinary Syndrome of Menopause
-
University of California, IrvineRecruitingGenitourinary Syndrome of MenopauseUnited States
-
Michigan Institution of Women's Health PCCompletedGenitourinary Syndrome of MenopauseUnited States
-
Stratpharma AGRecruitingGenitourinary Syndrome of MenopauseUnited States
-
Maltepe UniversityCompletedGenitourinary Syndrome of MenopauseTurkey
-
Fundación Santiago Dexeus FontRegen Lab SANot yet recruitingGenitourinary Syndrome of MenopauseSpain
-
Centro de Atenção ao Assoalho PélvicoRecruitingGenitourinary Syndrome of MenopauseBrazil
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedGenitourinary Syndrome of MenopauseItaly
-
King's College Hospital NHS TrustAlexandra Hospital, Athens, GreeceCompleted
-
Kanuni Sultan Suleyman Training and Research HospitalRecruitingGenitourinary Syndrome of MenopauseTurkey
-
Hacettepe UniversityCompletedGenitourinary Syndrome of MenopauseTurkey
Clinical Trials on Zinc
-
Hormozgan University of Medical SciencesCompleted
-
International Centre for Diarrhoeal Disease Research...Completed
-
Lesaffre InternationalCompleted
-
National University Hospital, SingaporeNational University, SingaporeCompletedDiabetes Mellitus, Non-Insulin-Dependent
-
CES UniversityNutreva S.A.S.; Foundation Child Care - FANCompleted
-
Instituto Nacional de Salud Publica, MexicoUNICEFCompletedDiarrhea, Infantile | Diarrhoea;AcuteMexico
-
Tufts UniversityBoston University; Boston Medical Center; Hebrew SeniorLifeCompletedDisorder of Immune Function
-
University of California, DavisBill and Melinda Gates Foundation; Helen Keller International; Université Polytechnique...Completed
-
University of UtahIntermountain Research and Medical FoundationTerminatedBronchopulmonary Dysplasia | Growth Failure | Infant,PrematureUnited States
-
UCSF Benioff Children's Hospital OaklandChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsCompleted